NOVAVAX INC
NVAX evidence brief
What we can confirm
- BioSniper Score:
- 5.5 / 10
- Market Cap:
- $1.62B
- Lead Asset:
- covid-19 vaccine (Approved)
What it means
What to watch
Prepared research question
What matters most for NVAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NVAX
Novavax Inc. (NVAX) is a biotechnology company transitioning from a COVID-19 vaccine-focused business to a partnership-driven model centered on its Matrix-M adjuvant technology, with a lean operating model and early-stage pipeline in infectious disease and oncology.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$1.62B
Cash Runway
—
Lead Asset
covid-19 vaccine (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 11 clinical trials for NOVAVAX INC.
Novavax Inc. (NVAX) is a biotechnology company transitioning from a COVID-19 vaccine-focused business to a partnership-driven model centered on its Matrix-M adjuvant technology, with a lean operating model and early-stage pipeline in infectious disease and oncology.
- Cash & equivalents of $191.5M as of 2026-06-30 [sec].
- Total revenue of $56.7M and net loss of -$53.4M for the latest reported period as of 2026-06-30 [sec].
- Shareholders' equity of -$190.7M as of 2026-06-30 [sec].
- Entered into a Pfizer License Agreement in January 2026 for use of Matrix-M adjuvant in up to two infectious disease areas [sec_mda · as of 2026-08-06].
- Positive Phase 3 trial results for COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates [sec · filed 2026-04-27].
What works
- Matrix-M adjuvant is being evaluated by multiple major pharmaceutical companies, including Pfizer and a top 10 oncology leader, under material transfer agreements [sec_mda · as of 2026-08-06].
- Positive Phase 3 results for COVID-19-Influenza combination and stand-alone influenza vaccine candidates demonstrate robust immune responses and tolerability [sec · filed 2026-04-27].
- Company has reduced non-GAAP combined R&D and SG&A expenses by 42% compared to 2024, indicating cost discipline [sec · filed 2026-04-27].
- Clostridioides difficile colitis vaccine candidate prioritized as potential next asset to enter clinic as early as 2027 [sec_mda · as of 2026-08-06].
What to weigh
- Net loss of -$53.4M and negative shareholders' equity of -$190.7M as of 2026-06-30 indicate ongoing financial strain [sec].
- Cash position declined from $857M as of December 31, 2025 to $191.5M as of June 30, 2026, reflecting significant cash burn [sec · filed 2026-04-27] [sec].
- Company did not close additional business development opportunities and partnerships during the 2025 performance period, missing a 30% target [sec · filed 2026-04-27].
- Forward-looking statements caution about ability to continue as a going concern through the next 12 months from issuance of financial statements [sec_mda · as of 2026-05-06].
From the filings
Quoted directly from source documents.
Cash position decline
“$857M | Cash position as of December 31, 2025(2)”
SEC filings · April 27, 2026
Pfizer License Agreement for Matrix-M
“In January 2026, we entered into the Pfizer License Agreement for use of Matrix-M ® adjuvant in up to two infectious disease areas.”
SEC MD&A · August 6, 2026
Positive Phase 3 results for combination vaccine
“Positive Phase 3 trial results for our COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates showed robust immune responses and were well tolerated”
SEC filings · April 27, 2026
C. diff vaccine candidate prioritized
“Clostridioides difficile colitis vaccine candidate was prioritized as the potential next asset to enter the clinic as early as 2027”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2020-09-28 · Phase3_Start — Phase 3 trial for SARS-CoV-2 recombinant spike protein nanoparticle vaccine with Matrix-M1 adjuvant in the UK.
- 2021-09-08 · Phase2_Start — Phase 1/2 study for quadrivalent hemagglutinin nanoparticle influenza and SARS-CoV-2 combination vaccine with Matrix-M1 adjuvant.
- 2022-02-28 · Trial_Readout — Readout on safety, immunogenicity, and efficacy of COVID-19 vaccine co-administered with seasonal influenza vaccine.
Risks & what to watch (3)›
Key risks
- Cash runway uncertainty — Cash dropped from $857M (Dec 2025) to $191.5M (Jun 2026); forward-looking statements note ability to continue as going concern for only next 12 months [sec] [sec_mda].
- Negative equity — Shareholders' equity of -$190.7M as of 2026-06-30 indicates liabilities exceed assets [sec].
- Partnership execution gap — Missed 30% target for closing additional business development deals in 2025 [sec · filed 2026-04-27].
What to watch
- Sanofi's commercial rollout of NUVAXOVID and associated milestone payments [news · published 2026-09-10].
- Progress of Clostridioides difficile vaccine candidate toward clinic entry as early as 2027 [sec_mda · as of 2026-08-06].
- Outcome of material transfer agreements with Pfizer and other partners for Matrix-M adjuvant [sec_mda · as of 2026-08-06].
- Cash burn rate and ability to maintain operations beyond 12 months [sec_mda · as of 2026-05-06].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run NOVAVAX INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NOVAVAX INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$53M
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 30.3%
- Days to cover
- 15.6
- Shares short
- 49,475,862
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NVAX short interestGovernance
Frequently asked questions
What is the AI investment thesis for NOVAVAX INC?
Novavax Inc. (NVAX) is a biotechnology company transitioning from a COVID-19 vaccine-focused business to a partnership-driven model centered on its Matrix-M adjuvant technology, with a lean operating model and early-stage pipeline in infectious disease and oncology.
What is NOVAVAX INC's lead drug candidate?
NOVAVAX INC's most advanced tracked candidate is covid-19 vaccine (Approved) for SARS-CoV Infection.
Who is the CEO of NOVAVAX INC?
Mr. John Charles Jacobs M.B.A. is the chief executive officer of NOVAVAX INC (NVAX).
Where is NOVAVAX INC headquartered?
NOVAVAX INC (NVAX) is headquartered in Gaithersburg, MD, United States.
What therapeutic areas does NOVAVAX INC focus on?
NOVAVAX INC develops therapies across Oncology, Immunology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.